Dyslipidemia in mild to moderate dementia patients. Perilla seed oil, Statin, Lipid level, Dementia
Conditions
Interventions
received two capsules of perilla seed oil three times per day before a meal three grams per day,received two capsules of perilla seed oil three times per day before a meal three grams per day for two
a perilla seed oil and statin group ,a perilla seed oil group ,a statin group ,group without perilla seed oil and statin
Sponsors
Center of Excellence in Stroke, Thammasat University
Eligibility
Sex/Gender
All
Age
50 Years to 90 Years
Inclusion criteria
Inclusion criteria: The patients were 50-90 years old and gained 10-23 scores measured by the Thai Mental State Examination (TMSE) or 7-20 scores measured by the Thai Montreal Cognitive Assessment (MoCA-Thai). They suffered from mild to moderate dementia based on the Diagnosis and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). They could recognize and communicate and gave written informed consent.
Exclusion criteria
Exclusion criteria: They were found to have creatinine greater than 2 mg/dL on the recruitment day. Their laboratory results showed 2.5 times greater abnormal liver function than the upper normal limit. The patients had treatable causes of dementia, such as vitamin B12 deficiency, hypothyroidism, normal pressure hydrocephalus, and neuro-syphilis. They had bleeding disorders. They were receiving warfarin or taking supplements. They suffered from major depression. They were allergic to medicinal and herbal medicines.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| lipid profile Baseline, 3 month, and 6 month post-dose Low Density Lipoprotein ,lipid profile Baseline, 3 month, and 6 month post-dose High Density Lipoprotein,lipid profile Baseline, 3 month, and 6 month post-dose Triglyceride,lipid profile Baseline, 3 month, and 6 month post-dose Total cholesterol,lipid profile Baseline, 3 month, and 6 month post-dose Low Density Lipoprotein/High Density Lipoprotein ratio | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood sugar Baseline, 3 month, and 6 month post-dose Fasting Blood Sugar,Blood sugar Baseline, 3 month, and 6 month post-dose Hemoglobin A1c ,Liver function levels Baseline, 3 month, and 6 month post-dose Serum glutamic oxaloacetic transaminase,Liver function levels Baseline, 3 month, and 6 month post-dose serum glutamic pyruvic transaminase,Renal function levels Baseline, 3 month, and 6 month post-dose Blood Urea Nitrogen,Renal function levels Baseline, 3 month, and 6 month post-dose Creatinine,Renal function levels Baseline, 3 month, and 6 month post-dose Glomerular Filtration Rate,complete blood count Baseline, 3 month, and 6 month post-dose White Blood Cell Count,complete blood count Baseline, 3 month, and 6 month post-dose Red blood cell ,complete blood count Baseline, 3 month, and 6 month post-dose Hematocrit,complete blood count Baseline, 3 month, and 6 month post-dose Neutrophil /Lymphocyte Platelet ratio | — |
Countries
Thailand
Contacts
Public ContactRapeebhorn Chanapuk
Thummasat University Hospital
Outcome results
None listed